Equities

Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.25
  • Today's Change-0.04 / -0.76%
  • Shares traded56.40k
  • 1 Year change-31.10%
  • Beta0.2598
Data delayed at least 15 minutes, as of Sep 20 2024 16:19 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform5
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for Fennec Pharmaceuticals Inc have a median target of 14.50, with a high estimate of 22.00 and a low estimate of 13.00. The median estimate represents a 174.10% increase from the last price of 5.29.
High315.9%22.00
Med174.1%14.50
Low145.7%13.00

Earnings history & estimates in USD

On Aug 13, 2024, Fennec Pharmaceuticals Inc reported 2nd quarter 2024 losses of -0.20 per share.
The next earnings announcement is expected on Nov 04, 2024.
Average growth rate+11.90%
Fennec Pharmaceuticals Inc reported annual 2023 losses of -0.600 per share on Mar 21, 2024.
Average growth rate-1.98%
More ▼

Revenue history & estimates in USD

Fennec Pharmaceuticals Inc. had 2nd quarter 2024 revenues of 7.26m. This missed the 11.05m consensus estimate of the 6 analysts following the company. This was 333.04% above the prior year's 2nd quarter results.
Average growth rate+58.18%
Fennec Pharmaceuticals Inc. had revenues for the full year 2023 of 21.25m. This was 1,284.50% above the prior year's results.
Average growth rate+592.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.